Olmesartan Ab (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olmesartan Ab, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Olmesartan Ab as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Ab belongs to the angiotensin II receptor blocker class and is used to manage elevated blood pressure.

- Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Primary hypertension: helps achieve clinician‑defined blood pressure goals. - High blood pressure: lowers cardiovascular risk by maintaining controlled blood pressure.

Olmesartan Ab may cause a range of adverse reactions.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue. - Abdominal discomfort. - Nasal congestion.

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue, or throat). - Hyperkalemia (elevated blood potassium levels). - Acute kidney injury or worsening renal function. - Severe hypotension. - Hepatic injury or abnormal liver enzymes.

Before initiating therapy, clinicians should consider several safety measures.

- Blood pressure monitoring: ensure target levels are reached without excessive drop. - Renal function assessment: evaluate serum creatinine and eGFR periodically. - Electrolyte checks: monitor potassium, especially if combined with potassium‑sparing agents. - Pregnancy avoidance: drug is Category D; discontinue if pregnancy is confirmed. - Elderly caution: start at lower dose and titrate slowly. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Olmesartan Ab can interact with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment. - Potassium‑sparing diuretics or supplements: risk of hyperkalaemia. - ACE inhibitors: additive effect on potassium and renal function. - NSAIDs (e.g., ibuprofen, naproxen): may diminish antihypertensive effect and affect renal perfusion. - Lithium: increased lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance hypotensive response. - Rifampin or other strong inducers: may reduce olmesartan plasma levels. - CYP450 inhibitors (rare): potential modest increase in drug exposure.